Why Is Autolus Therapeutics Stock Trading Higher On Tuesday?
NICE recommends Aucatzyl for NHS use in r/r B-ALL patients. Aucatzyl will have routine NHS commissioning availability. Autolus plans an imminent launch in England and Wales. Conditional marketing authorization from MHRA was granted in April 2025. AUTL stock rose 10.48% to $1.37 at publication.
View signal analysis